Congress Asset Management Co. Acquires 18,919 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)

Congress Asset Management Co. increased its holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 9.0% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 227,989 shares of the company’s stock after buying an additional 18,919 shares during the quarter. Congress Asset Management Co. owned about 0.21% of Tango Therapeutics worth $704,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Catalina Capital Group LLC purchased a new position in shares of Tango Therapeutics during the fourth quarter valued at approximately $82,000. Quest Partners LLC raised its stake in Tango Therapeutics by 1,448.4% during the 3rd quarter. Quest Partners LLC now owns 10,885 shares of the company’s stock valued at $84,000 after buying an additional 10,182 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Tango Therapeutics during the 3rd quarter valued at $151,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Tango Therapeutics by 64.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock valued at $159,000 after buying an additional 8,055 shares during the period. Finally, Intech Investment Management LLC purchased a new position in shares of Tango Therapeutics in the 3rd quarter worth $238,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on TNGX. HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of Tango Therapeutics in a research report on Friday, November 8th. B. Riley lowered their price objective on shares of Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Guggenheim cut their target price on shares of Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tango Therapeutics in a report on Thursday, December 5th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $12.33.

Tango Therapeutics Trading Down 1.6 %

NASDAQ TNGX opened at $2.43 on Wednesday. Tango Therapeutics, Inc. has a 12 month low of $2.41 and a 12 month high of $12.10. The stock has a market cap of $261.03 million, a price-to-earnings ratio of -2.06 and a beta of 0.80. The company’s 50 day moving average is $2.98 and its two-hundred day moving average is $5.70.

Insider Transactions at Tango Therapeutics

In related news, CEO Barbara Weber sold 9,778 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total value of $29,236.22. Following the completion of the transaction, the chief executive officer now owns 1,631,264 shares of the company’s stock, valued at approximately $4,877,479.36. This represents a 0.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 24,268 shares of company stock valued at $72,561 over the last three months. Corporate insiders own 6.30% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.